Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 9/20 | 0.76 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.76 |
| ▸ | CYP1A2 | P05177 | 8/20 | 0.76 |
| ▸ | CYP3A4 | P08684 | 8/20 | 0.76 |
| ▸ | CYP1A1 | P04798 | 7/20 | 0.76 |
| ▸ | CYP1B1 | Q16678 | 7/20 | 0.76 |
| ▸ | XDH | P47989 | 7/20 | 0.76 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.76 |
| ▸ | ABCB1 | P08183 | 6/20 | 0.76 |
| ▸ | FTO | Q9C0B1 | 6/20 | 0.76 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.76 |
| ▸ | MAPT | P10636 | 6/20 | 0.76 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.76 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.76 |
| ▸ | ALOX15 | P16050 | 5/20 | 0.76 |
| ▸ | APP | P05067 | 5/20 | 0.76 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.76 |
| ▸ | IPMK | Q8NFU5 | 5/20 | 0.76 |
| ▸ | IP6K2 | Q9UHH9 | 5/20 | 0.76 |
| ▸ | BCHE | P06276 | 4/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23919099 | 0.93 | MEN1 (0.65) | MEN1KMT2ACYP1A2CYP3A4CYP1A1 | |
| SCHEMBL9565912 | 0.89 | POLH (0.65) | MEN1KMT2ACYP1A2CYP3A4CYP1A1 | |
| SCHEMBL9909444 | 0.87 | MEN1 (0.75) | MEN1KMT2ACYP1A2CYP3A4CYP1A1 | |
| Kaempferol SCHEMBL30655455 | 0.87 | MEN1 (1.00) | MEN1KMT2ACYP1A2CYP3A4CYP1A1 | |
| Kaempferol SCHEMBL18817 | 0.87 | MEN1 (1.00) | MEN1KMT2ACYP1A2CYP3A4CYP1A1 | |
| Kaempferol SCHEMBL1259228 | 0.87 | MEN1 (1.00) | MEN1KMT2ACYP1A2CYP3A4CYP1A1 | |
| Kaempferol SCHEMBL29378805 | 0.87 | MEN1 (1.00) | MEN1KMT2ACYP1A2CYP3A4CYP1A1 | |
| SCHEMBL12455834 | 0.87 | CYP1A1 (0.79) | MEN1KMT2ACYP1A2CYP3A4CYP1A1 | |
| SCHEMBL14254533 | 0.86 | MEN1 (0.58) | MEN1KMT2ACYP1A2CYP3A4CYP1A1 | |
| SCHEMBL8042944 | 0.86 | ABCB1 (0.81) | MEN1KMT2ACYP1A2CYP3A4CYP1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230272061-A1 | TL1A PATIENT SELECTION METHODS, SYSTEMS, AND DEVICES | PROMETHEUS BIOSCIENCES, INC. | 2023-08-31 | — | — | US | disclosed |
| US-9757407-B2 | Treatment of viral infections by modulation of host cell metabolic pathways | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2017-09-12 | — | — | US | disclosed |
| US-20160346309-A1 | TREATMENT OF VIRAL INFECTIONS BY MODULATION OF HOST CELL METABOLIC PATHWAYS | UNIV PRINCETON (US) | 2016-12-01 | — | — | US | disclosed |
| US-20150139949-A1 | ANTI-VIRAL COMBINATION THERAPY | KOYUNCU EMRE (US) | 2015-05-21 | — | — | US | disclosed |
| US-9029413-B2 | Treatment of viral infections by modulation of host cell metabolic pathways | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2015-05-12 | — | — | US | disclosed |
| US-20130065850-A1 | TREATMENT OF VIRAL INFECTIONS BY MODULATION OF HOST CELL METABOLIC PATHWAYS | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2013-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230272061-A1 | TL1A PATIENT SELECTION METHODS, SYSTEMS, AND DEVICES | TLL1, TLN1, TSG101 | MEN1 1295/4885KMT2A 292/4885CYP1A2 4505/4885 |
| US-20160346309-A1 | TREATMENT OF VIRAL INFECTIONS BY MODULATION OF HOST CELL METABOLIC PATHWAYS | GOT2, MAVS, ME3 | MEN1 4221/4885KMT2A 3171/4885CYP1A2 559/4885 |
| US-20130065850-A1 | TREATMENT OF VIRAL INFECTIONS BY MODULATION OF HOST CELL METABOLIC PATHWAYS | GOT2, MAVS, ME3 | MEN1 4221/4885KMT2A 3171/4885CYP1A2 559/4885 |
| US-20150139949-A1 | ANTI-VIRAL COMBINATION THERAPY | HAVCR2, MAVS, ZC3HAV1 | MEN1 4738/4885KMT2A 3077/4885CYP1A2 3247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.